多西紫杉醇
医学
内科学
肺癌
肿瘤科
随机对照试验
多中心试验
多中心研究
化疗
作者
Xingxiang Pu,Zemin Xiao,Jia Li,Zhijun Wu,Zhongxia Ma,Jie Weng,Maoliang Xiao,Yanhua Chen,Yongqing Cao,Peiguo Cao,Qianzhi Wang,Xu Yan,Kang Li,Bolin Chen,Xu Fang,Liyu Liu,Yi Kong,Hui Zhang,Huaxin Duan,Lin Wu
出处
期刊:Lung Cancer
[Elsevier]
日期:2024-03-18
卷期号:191: 107538-107538
被引量:8
标识
DOI:10.1016/j.lungcan.2024.107538
摘要
Anlotinib plus docetaxel offers a viable therapeutic alternative for patients with advanced NSCLC who failed first-line platinum-based treatments.
科研通智能强力驱动
Strongly Powered by AbleSci AI